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Summary
Vitamin D deficiency is associated with increased incidence and severity
of various immune-mediated diseases. Active vitamin D (1a,25-dihydrox-
yvitamin D3; 1,25(OH)2D3) up-regulates CD4
+ T-cell expression of the
purine ectonucleotidase CD39, a molecule that is associated with the gen-
eration of anti-inflammatory adenosine. Here we aimed to investigate the
direct impact of 1,25(OH)2D3 on expression of the downstream ecto-
50-nucleotidase CD73 by human CD4 T cells, and components of the
transforming growth factor-b (TGF-b) pathway, which have been impli-
cated in the modulation of CD73 by murine T cells. At 108 to 107 M,
1,25(OH)2D3 significantly increased expression of CD73 on peripheral
human CD4+ T cells. Although 1,25(OH)2D3 did not affect the mRNA
expression of latent TGF-b1, 1,25(OH)2D3 did up-regulate expression of
TGF-b-associated molecules [latency-associated peptide (LAP), gly-
cophorin A repetitions predominant (GARP), GP96, neuropilin-1, throm-
bospondin-1 and av integrin] which is likely to have contributed to the
observed enhancement in TGF-b bioactivity. CD73 was highly co-ex-
pressed with LAP and GARP following 1,25(OH)2D3 treatment, but unex-
pectedly, each of these cell surface molecules was expressed primarily on
CD4+ Foxp3– T cells, rather than CD4+ Foxp3+ T cells. Notably, neutral-
ization of TGF-b significantly impaired 1,25(OH)2D3-mediated induction
of CD73. Collectively, we show that 1,25(OH)2D3 enhances expression of
CD73 on CD4+ Foxp3– T cells in a process that is at least partially
TGF-b-dependent. These data reveal an additional contributing mecha-
nism by which vitamin D may be protective in immune-mediated disease.
Keywords: 1a,25-dihydroxyvitamin D3; CD73; Foxp3; transforming
growth factor-b.
Introduction
Vitamin D insufficiency has been negatively associated
with multiple immune-mediated diseases which is believed
to be attributed to its numerous immunomodulatory
properties (recently reviewed in refs 1,2). We and others
have shown that the frequency of Foxp3+ regulatory T
cells can be increased by either high concentrations
(106 M) of the active form of vitamin D (1a,25-dihydrox-
yvitamin D3; 1,25(OH)2D3), or lower doses (10
7 to 8
M)
in the presence of high T-cell stimulation.3,4 Between 107
and 108 M 1,25(OH)2D3 can also increase the frequency
of a population of regulatory CD4+ IL-10+ Foxp3– T
cells.3 Importantly these experimental data are supported
by in vivo evidence whereby serum vitamin D status is
positively associated with the frequency of Foxp3+ T cells
in the periphery and airways, as well as levels of IL-10 in
the airways.3,5–7 The downstream effects of 1,25(OH)2D3
are significantly influenced by the cytokine milieu,
such that the combination of 1,25(OH)2D3 and
Abbreviation: 1,25(OH)2D3, 1a,25-dihydroxyvitamin D3
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transforming growth factor-b1 (TGF-b1) induces Foxp3
expression to a greater extent than either compound
alone.8
Regulatory T cells employ various immunoregulatory
mechanisms including the secretion of immunosuppres-
sive cytokines such as interleukin-10 (IL-10) and TGF-b,
as well as modulating dendritic cell behaviour and gran-
zyme deployment.9 Of particular relevance here, cells can
take up extracellular adenosine by two main mechanisms,
either through specific adenosine transporters or through
binding to one of four G-protein-coupled P1 purinergic
receptors (A1, A2A, A2B and A3). Binding to the
purinergic receptors can result in suppression of T-cell
receptor signalling and induction of various
immunomodulatory effects as reviewed elsewhere.10–12 In
contrast, ATP is sensed by P2X and P2Y purinergic recep-
tors and generally promotes a pro-inflammatory environ-
ment.13 The cell surface ecto-enzymes CD39
(ectonucleoside triphosphate dephosphorylase) and CD73
(ecto-50-nucleotidase) regulate levels of ATP and adeno-
sine, and therefore inflammation, by dephosphorylating
ATP into ADP and AMP (CD39), and then into adeno-
sine (CD73).10,11 We have previously shown that 1,25
(OH)2D3 can modulate this pathway by increasing
expression of CD39 on peripheral blood human CD4+ T
cells, which contributes to dampening IL-17A secretion.14
A multifaceted cytokine, TGF-b is involved in processes
such as differentiation of T helper type 17 cells and Fox-
p3+ regulatory T cells, proliferation of CD4+ T cells and
innate immune cell chemotaxis.15 Humans express three
TGF-b isoforms (TGFb1–3), all of which are synthesized
in a latent form bound to latency-associated peptide
(LAP) either alone or with latent TGF-b binding protein.
Latent TGF-b can be expressed on the cell surface by the
transmembrane orphan toll-like receptor glycophorin A
repetitions predominant (GARP), which itself requires the
chaperone heat-shock protein GP96 for correct conforma-
tional folding.16 The active form of TGF-b is only
released following cleavage of LAP or conformational
remodelling by a range of molecules including neu-
ropilin-1, thrombospondin-1 and various av integrins.
17,18
The active moiety can then bind to a heterodimer of type
I and II TGF-b receptors to mediate downstream
effects.15,19
Cross-talk between the TGF-b and adenosine pathways
is indicated by the fact that treating mouse CD4+ T cells
with TGF-b increases expression of CD73, and in CD73
knockout mice, experimental induction of TGF-b mRNA
was blocked.20,21 Furthermore, the ability of CD4+ CD73+
T cells to delay the development of diabetes in a mouse
model was impaired by anti-TGF-b, indicating a key pro-
tective role for this cytokine.22
1,25(OH)2D3 is known to enhance the frequency of
human CD4+ CD39+ T cells; however, whether it controls
the expression of the related ecto-50-nucleotidase CD73 is
unknown. We further investigated the role of TGF-b in
this process given existing evidence for cross-talk between
the purine and TGF-b pathways in mice.
Materials and methods
Cell isolation and culture
Ethical approval was granted by Guy’s Hospital Ethics
Committee (09/H0804/77) and full written informed
consent was obtained from all donors. CD4+ cells were
isolated from peripheral venous blood as previously
described using Dynabeads (Invitrogen, Paisley, UK).3
Then, 1 9 106 cells/ml were cultured in RPMI-1640
containing 10% fetal calf serum, 2 mM L-glutamine and
50 lg/ml gentamycin, and stimulated with plate-bound
anti-CD3 (1 lg/ml; OKT-3) and 50 IU/ml recombinant
human IL-2 (Eurocetus, Harefield, UK) in the presence
or absence of 1,25(OH)2D3 (BIOMOL Research Labs,
Exeter, UK). For cultures going beyond 7 days, cells
were counted and re-stimulated at 1 9 106 cells/ml on
day 7 with fresh medium containing drugs. Where rele-
vant, anti-TGF-b1–3 or an isotype control (5 lg/ml;
R&D Systems, Abingdon, UK) was added to the
cultures on days 0 and 7. Viability did not signifi-
cantly differ between culture conditions (data not
shown).
Quantitative RT-PCR
RNA was extracted from cell pellets using the RNeasy
Mini kit (Qiagen, Crawley, UK) according to the manu-
facturer’s instructions and quantified using a Nanodrop
ND-1000 spectrophotometer (ThermoScientific, Wilming-
ton, NC). RNA (250 ng) was reverse transcribed into
cDNA then quantitative RT-PCR was performed in tripli-
cate using an Applied Biosystems 7900 HT system and
FAM labelled assay-on-Demand reagent sets (cd73 – Hs00
159686_m1; tgfb1 – Hs00998133_m1; lrrc32 – Hs0019
4136_m1; gp96 – Hs00427665_g1; nrp-1 – Hs00826
128_m; tsp-1 – Hs00962908_m1; av integrin – Hs00233
808_m1). Quantitative RT-PCR were multiplexed using
VIC-labelled 18s probe (Hs99999901_s1) as an endoge-
nous control and analysed using SDS software version 21
(Applied Biosystems, Foster City, CA) in accordance with
the 2(ΔΔCt) method.
Flow cytometry
The following antibodies were used for cell surface phe-
notyping – CD73 (AD2; eBiosciences, Hatfield, UK),
GARP and LAP (7B11 and TW4-2F8, respectively; Biole-
gend, London, UK). Where relevant, cells were further
stained for intranuclear Foxp3 (PCH101; eBiosciences)
using the eBiosciences Foxp3 staining kit as per the man-
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ufacturer’s instructions. Unstained cells, isotype controls,
single cell stains and fluorescence minus one controls
were employed. Dead cells (7-aminoactinomycin D posi-
tive; Sigma-Aldrich, Gillingham, UK) were gated out.
ATP assay
After 7 days of culture alone or in the presence of 107 M
1,25(OH)2D3, 25,000 CD4
+ T cells were seeded in 100 ll
culture medium with 500 lM ATP. Consumption of ATP
was assessed 90 minutes later using a CellTiter-Glo Lumi-
nescent Cell Viability Assay (Promega, Southampton,
UK) in accordance with the manufacturer’s instructions.
A standard curve was generated immediately before run-
ning the assay by dissolving ATP disodium salt hydrate
(Sigma-Aldrich) in cell culture medium (100 pM to
100 mM).
Suppression assay
CD4+ T cells were cultured with 107 M 1,25(OH)2D3 for
7 days as described, then live cells (7-aminoactinomycin-
D-negative) were sorted based on CD73 expression using
a BD FACSAria (BD Biosciences, Oxford, UK). CD73– or
CD73+ cells were subsequently cultured at a ratio of
025 : 1 with freshly isolated autologous CellTrace violet-
labelled CD4+ T cells for a further 7 days. Cell prolifera-
tion was assessed by the loss in fluorescence intensity of
CellTrace Violet on an NxT attune (Life Technologies,
Paisley, UK).
TGF-b bioassay
Bioactivity of TGF-b was assessed using mink lung
epithelial cells transfected with a construct containing the
50 end of the human plasminogen activator inhibitor-1
gene fused to the firefly luciferase reporter gene (kindly
donated by Prof. Daniel B Rifkin; New York Univer-
sity).23 Then, 3 9 105 mink lung epithelial cells/ml were
incubated for 14 hr at 37°C in 5% CO2 with cell culture
supernatants. Culture media were aspirated, cells were
lysed and then luciferase activity (which corresponds to
TGF-b activity) was determined using a Biotium Firefly
Luciferase Assay Kit (Promega, Southampton, UK) in
accordance with the manufacturer’s instructions. Serum-
free RPMI-1640 was used for these experiments due to
high levels of TGF-b found in fetal calf serum.
Data analysis
Flow cytometry data were analysed using FLOWJO (Trees-
tar Inc., Ashland, OR; version 10) and cumulative data
analysis was performed in GRAPHPAD PRISM version 600
for Windows (Graphpad Software Inc., San Diego, USA).
Data were assessed for Gaussian distribution and the
appropriate statistical test was then performed as
described in the figure legends. Data are shown as mean
 standard error of mean.
Results
1,25(OH)2D3 up-regulates CD4
+ T-cell expression of
CD73
It has previously been shown that human CD4+ T cells
cultured in the presence of 107 M 1,25(OH)2D3 express
elevated levels of CD39.14 Here this observation is
extended to reveal that expression of downstream ecto-50-
nucleotidase CD73 is also significantly up-regulated at the
gene (Fig. 1a) and protein level (% CD73+ cells and mean
fluorescence intensity; Fig. 1b and c) following 7 or
14 days culture with 1,25(OH)2D3. Furthermore, a trend
towards lower ATP levels 90 min after spiking cells with
500 lM ATP was observed in 1,25(OH)2D3-treated CD4
+
T cells (P = 006; see Supplementary material, Fig. S1A).
CD73+ cells were also shown to be regulatory because
they suppressed the proliferation of autologous CellTrace
Violet-labelled CD4+ T cells (ratio of 025 : 1) to a
greater extent than CD73– cells (lower percentage of cells
divided (P < 005) and division index (P = 009); see
Supplementary material, Figure S1B,C).
1,25(OH)2D3 up-regulates expression of TGFb-
associated molecules
To investigate whether enhancement of CD73 expression
was TGF-b dependent, we first assessed the impact of
1,25(OH)2D3 on components of the TGF-b pathway.
After 7 and 14 days in culture alone or in the presence of
the indicated concentration of 1,25(OH)2D3, CD4
+ T-cell
expression of latent tgfb2 and tgfb3 was typically unde-
tectable by quantitative RT-PCR (data not shown).
Although latent tgfb1 was highly expressed at the mRNA
level, its expression was not modulated by 1,25(OH)2D3
treatment (Fig. 2a). In contrast, lrrc32 (gene for GARP)
mRNA was significantly up-regulated by 1,25(OH)2D3
with a trend (P = 013) towards increased expression of
gp96, a chaperone for GARP, by day 14. At the protein
level, 1,25(OH)2D3 treatment significantly increased over-
all expression of GARP and LAP as well as the percentage
of cells co-expressing both of these molecules (Fig. 2b–d).
In order to generate active TGF-b, LAP must be
cleaved. Within the immune cell compartment, this is
reported to be primarily carried out by the cell surface
expressed molecules thrombospondin-1, neuropilin-1 and
av integrin,
17,18 each of which were also up-regulated by
1,25(OH)2D3 treatment at the mRNA level, most notably
after 14 days in culture (P = 009, P < 005 and P < 005,
respectively; Fig. 2e, and see Supplementary material,
Fig. S2).
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1,25(OH)2D3-mediated up-regulation of CD73, LAP
and GARP occurs primarily on CD4+ Foxp3– T cells
Foxp3 is conventionally seen as the lineage defining tran-
scription factor of natural and induced regulatory T cells,
but Foxp3– suppressor cells do exist.24 As the purinergic
and TGF-b pathways have been linked to the function of
regulatory T cells,9 the interaction between intranuclear
Foxp3 expression and surface expression of CD73, LAP
and GARP was assessed. In agreement with previous find-
ings, no significant increase in Foxp3 expression was
observed in the presence of 107 M 1,25(OH)2D3
(Fig. 3).3 Furthermore, 1,25(OH)2D3-mediated up-regula-
tion of CD73 (Fig. 3a, b), GARP (Fig. 3c, d) and LAP
(Fig. 3e, f) was principally seen on CD4+ Foxp3– T cells
as opposed to CD4+ Foxp3+ cells.
Cross-talk between CD73 and TGF-b in 1,25
(OH)2D3-treated CD4
+ T cells
Mouse studies have shown that cross-talk can occur
between the adenosine and TGF-b pathways,20,22 but
whether this is true in humans and any impact of 1,25
(OH)2D3 remains to be ascertained. Indeed, cell surface
staining showed a significant increase in the percentage of
cells co-expressing CD73 with TGF-b-associated molecules
LAP, GARP and neuropilin -1 following 1,25(OH)2D3
treatment (Fig. 4).
Furthermore, TGF-b bioactivity was elevated in super-
natants harvested after 7 days of culture with 1,25
(OH)2D3 (P = 009), as determined using mink lung
epithelial cells and a luciferase assay (Fig. 5a). These
observations were extended by culturing CD4+ T cells in
the presence of a neutralizing TGF-b antibody or the rele-
vant isotype control. Anti-TGF-b impaired the 1,25
(OH)2D3-mediated induction of CD73 at the mRNA level
(P = 008; Fig. 5a) and in both the percentage of
CD4+ CD73+ T cells and the mean fluorescence intensity
of CD73 (P < 005; Fig. 5b).
Discussion
The frequency of regulatory T-cell populations is known
to be enhanced by vitamin D both in vitro and in vivo.
However, how these cells suppress in different environ-
ments and what markers identify them is not clear.3,4 The
focus of this work was to assess the immunomodulatory
effects of 1,25(OH)2D3 on the induction of two complex
immunoregulatory molecules, CD73 and TGF-b.
In the present study a significant up-regulation of
CD73 expression in CD4+ T cells by 1,25(OH)2D3 was
observed, complimenting the previously published finding
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Figure 1. 1a,25-dihydroxyvitamin D3 (1,25
(OH)2D3) up-regulates CD73 expression on
CD4+ T cells. CD4+ T cells stimulated with
anti-CD3 and interleukin-2 (IL-2) for 7 or
14 days alone () or in the presence of the
indicated concentration of 1,25(OH)2D3
(10x M). (a) Relative gene expression of cd73
as determined by quantitative RT-PCR at days
7 (n = 8) and 14 (n = 6). (b) Representative
histograms of CD73 expression (bold line)
compared with isotype control (grey shaded).
(c) Cumulative data of the percentage of
CD4+ CD73+ T cells (c i) and CD73 mean flu-
orescence intensity (c ii) at days 7 (top; n = 8)
and 14 (bottom, n = 6). Data assessed by
repeated measures one-way analysis of variance
with Tukey’s multiple comparison test.
*P ≤ 005; **P ≤ 001.
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that 1,25(OH)2D3 enhances surface expression of CD39.
14
Heightened expression of these two ecto-nucleotidases
most likely contributes to the observed faster consump-
tion of ATP by 1,25(OH)2D3-treated cells (Fig. S1A) and
to the enhanced generation of downstream adenosine.25
Studies have shown that CD73 is critical in mediating
many immunosuppressive properties of cells in mice and
man26,27 and that adenosine can impair T-cell prolifera-
tion in humans.28,29 The latter data correlate with the
anti-proliferative properties of CD73+ cells that are
reported both here and elsewhere.30 As well as the
traditional CD39 and CD73 pathway for ATP catabolism,
a CD39-independent pathway involving CD38 and CD73
has been documented in human T cells.31 As CD38 is
known to be highly up-regulated on T cells in response
to 1,25(OH)2D3,
3,32 we hypothesize that 1,25(OH)2D3 is
further enhancing ATP breakdown and adenosine genera-
tion by acting via the CD39-dependent and -independent
pathways.
Since 107 M 1,25(OH)2D3 has previously been shown
to increase the frequency of CD4+ Foxp3+ cells in the
presence of TGF-b,8 the relationship between 1,25
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Figure 2. 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3) up-regulates expression of transforming growth factor-b (TGF-b) -associated molecules.
CD4+ T cells stimulated (anti-CD3/IL-2) for 7 or 14 days alone () or in the presence of the indicated concentration of 1,25(OH)2D3 (10x M).
(a) Relative gene expression of tgfb1, lrrc32 and gp96 at days 7 (top) and 14 (bottom) as determined by quantitative RT-PCR [n = 7; repeated
measures one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test]. Representative histograms (b) and dot plots (c) of gly-
cophorin A repetitions predominant (GARP) and latency-associated peptide (LAP) expression at day 14. (d) Cumulative data showing the fre-
quency of GARP+ (left), LAP+ (middle) and LAP+GARP+ (right) CD4+ T cells at day 7 (top) and day 14 (bottom) (n = 7; repeated measures
one-way ANOVA with Tukey’s multiple comparison test). (e) Relative gene expression of thrombospondin-1, neuropilin-1 and av integrin at day 14
as determined by quantitative RT-PCR (n = 8; paired t-test). *P ≤ 005; **P ≤ 001.
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(OH)2D3 and TGF-b was investigated further. 1,25
(OH)2D3 increased expression of LAP (component of
latent TGF-b), GARP (latent TGF-b receptor) and GP96
(latent TGF-b chaperone), which together result in cells
that have an enhanced capacity to both generate and
present latent TGF-b. These data are in line with a
study in patients with multiple sclerosis in whom vita-
min D supplementation resulted in increased levels of
LAP in the serum relative to those in the placebo
group.33 Although a whole host of molecules and envi-
ronmental conditions such as heat and extreme pH have
been implicated in activating TGF-b by cleaving LAP, av
integrins, neuropilin-1 and thrombospondin-1 are the
primary mediators within the immune cell compart-
ment;18 here expression of each of these molecules, at
least at the mRNA level, was shown to be higher in 1,25
(OH)2D3-treated cells, which most likely contributed to
the enhanced TGF-b bioactivity observed.
In addition to its anti-inflammatory role, TGF-b is
involved in tissue remodelling and therefore can have
potentially negative consequences in diseases such as
asthma.34 However, 1,25(OH)2D3 has also been shown
to inhibit the proliferation of airway smooth muscle
cells.35 Moreover, in utero vitamin D deficiency in mice
leads to increased airway smooth muscle mass and air-
way resistance36 and in children with severe asthma,
lower levels of vitamin D were associated with increased
airway smooth muscle mass.37,38 As with many in vitro
studies, the data presented here are observational.
Actual levels of molecules as well as their expression
relative to other mediators in vivo are critical; for
example, lung remodelling in mice has been shown to
result from an imbalance between TGF-b1 and bone
morphogenic protein 7 (BMP-7).39 Whether TGF-b acts
in a regulatory or tissue remodelling manner in various
disease contexts is most likely dependent on the
cytokine milieu as a whole and so warrants studying
in vivo.
A major limitation in the study of regulatory T cells is
a lack of specific cell surface markers, particularly in
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humans.40,41 Foxp3 is a widely accepted marker of many
regulatory T-cell populations, but is intracellular so cells
must be permeabilized in order to perform staining,
which limits the isolation of pure and live cells. Since
CD73, GARP and LAP are putative markers of regulatory
T cells,42–44 their relationship with Foxp3 was examined
in our culture conditions. CD73 was expressed primarily
on CD4+ Foxp3– T cells and 1,25(OH)2D3-mediated
induction of CD73, GARP and LAP was only clearly evi-
dent on CD4+ Foxp3– T cells. In support of this, Foxp3
expression has been found to be independent of GARP
expression in cells from HIV-positive patients.45 Although
not absolute markers, these data support the idea that
CD73, GARP and LAP help to identify Foxp3– regulatory
cells.
Previous studies have shown that cross-talk between
the TGF-b and adenosine pathways exists in mice,20–22
and here we confirm this in humans too. A significant
proportion of CD4+ T cells co-express CD73 with GARP,
LAP and neuropilin-1 following 1,25(OH)2D3 treatment
and by impairing TGF-b activity, the induction of CD73
by 1,25(OH)2D3 was reduced.
A high concentration of 1,25(OH)2D3 (10
8/7
M/10–
100 nM) was used throughout this work for optimal
in vitro responses, although trends were seen at 109 M
(data not shown). Previous in vitro studies have shown
that monocyte-derived DCs, alveolar macrophages and
bronchial epithelial cells express the enzyme 25-hydrox-
yvitamin D3-1a-hydroxylase and can consequently pro-
duce up to 5 9 109 M functional 1,25(OH)2D3 from 25
(OH)D.46–49 Although the levels of 1,25(OH)2D3 pro-
duced depend upon the concentration of 25(OH)D,50
there is evidence that systemic levels of 1,25(OH)2D3
may not reflect an individual’s vitamin D status;51 these
findings highlight the importance of local conversion of
25(OH)D within immune tissues producing currently
undefined levels of 1,25(OH)2D3.
In summary, we show that 1,25(OH)2D3 can enhance
expression of CD73 on CD4+ Foxp3– T cells in part by
up-regulating autocrine TGF-b bioactivity. These data
help to further elucidate the mechanisms by which vita-
min D may skew the immune system towards a more
regulatory phenotype and consequently protect against
various immune-mediated diseases. Further work to
probe the functional consequences of these observations
is warranted both in vitro and in vivo.
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